CLINICAL TRIALS PROFILE FOR NAPROXEN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for NAPROXEN
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00410995 ↗ | Effects of Naproxen on Physical Performance | Terminated | University of Oklahoma | Phase 4 | 2004-05-01 | The purpose of this study is to determine the effect of daily use of Naproxen (a commonly used over-the-counter NSAID) on the physical performance of athletes, as measured by maximum oxygen consumption. |
| OTC | NCT00751400 ↗ | Naproxen Sodium Extended-Release Actual Use Study | Completed | Pegus Research, Inc. | Phase 3 | 2008-07-01 | The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment. |
| OTC | NCT00751400 ↗ | Naproxen Sodium Extended-Release Actual Use Study | Completed | Bayer | Phase 3 | 2008-07-01 | The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for NAPROXEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001955 ↗ | Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions) | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | 1999-12-01 | This 2-part study will evaluate the effectiveness and side effects of two anti-inflammatory drugs for relieving pain and improving jaw function in patients with temporomandibular disorder (TMD). Part 1 will evaluate celecoxib (Celebrex); Part 2 will evaluate etanercept (Enbrel). The Food and Drug Administration has approved both of these drugs for treating certain forms of arthritis. Patients between the ages of 18 and 65 years with painful jaw joint conditions may be eligible for this study. Candidates will complete several written questionnaires about their jaw condition and will undergo a medical history, complete TMD evaluation, blood and urine tests, and imaging studies of the temporomandibular joint, such as X-rays and magnetic resonance imaging. Patients will rate the quality and intensity of their pain before beginning treatment. At certain periods during the study, they will also keep a pain diary, twice a day recording the intensity and magnitude of their pain. Part 1 - Celecoxib: Patients will be randomly assigned to receive either 1) celecoxib twice a day by mouth; 2) naproxen (a non-steroidal anti-inflammatory drug) twice a day by mouth; or 3) a placebo (inactive pill) twice a day by mouth. Part 2 - Etanercept: Patients will be randomly assigned to receive either 1) etanercept injected under the skin or 2) saline (an inactive placebo) injected under the skin. Patients in this group will also undergo two aspirations of fluid from the jaw joint - once before treatment begins and again 6 weeks later. For this procedure, the joint is numbed with an anesthetic and then a needle is inserted into the jaw space to withdraw fluid, which will be analyzed for inflammatory processes in the joint. All patients will have a final evaluation 6 weeks after beginning treatment, including a TMD physical examination, laboratory and X-ray tests as required. The pain diary and questionnaires will be collected at this visit. |
| NCT00004845 ↗ | A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study) | Completed | Alzheimer's Disease Cooperative Study (ADCS) | Phase 2/Phase 3 | 1969-12-31 | The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog. |
| NCT00004845 ↗ | A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study) | Completed | National Institute on Aging (NIA) | Phase 2/Phase 3 | 1969-12-31 | The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NAPROXEN
Condition Name
Clinical Trial Locations for NAPROXEN
Trials by Country
Clinical Trial Progress for NAPROXEN
Clinical Trial Phase
Clinical Trial Sponsors for NAPROXEN
Sponsor Name
